BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15939920)

  • 1. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
    Lehmann J; Retz M; Wiemers C; Beck J; Thüroff J; Weining C; Albers P; Frohneberg D; Becker T; Funke PJ; Walz P; Langbein S; Reiher F; Schiller M; Miller K; Roth S; Kälble T; Sternberg D; Wellek S; Stöckle M;
    J Clin Oncol; 2005 Aug; 23(22):4963-74. PubMed ID: 15939920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
    BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS; Tzai TS; Chow NH
    Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
    Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
    Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
    Freiha F; Reese J; Torti FM
    J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
    Voce S; Montanari F; Arnone S; Dal Pozzo C; Suprani G; Cerullo G; Fornarola V
    Arch Esp Urol; 1992 Jun; 45(5):491-8. PubMed ID: 1510485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study.
    Petrioli R; Frediani B; Manganelli A; Barbanti G; De Capua B; De Lauretis A; Salvestrini F; Mondillo S; Francini G
    Cancer; 1996 Jan; 77(2):344-51. PubMed ID: 8625244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
    Galante E; Ferroni C; Bianchi S; Megale C; Molinaro S; Maymone S
    J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.